article thumbnail

Meet the 2023 Social Impact Category Winner: Takeda SA

ISPE

For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.

article thumbnail

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part ii)

pharmaphorum

This includes vaccines which prevent diseases, such as for HPV papilloma, which is already part of the European plan. With 90% of adolescents that should be vaccinated by 2030, Luppi deems it an opportunity. Everyone has a mobile: now is the age of electronic patient information; now is the time for electronic labelling.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AZ, Sanofi get first green light for RSV prophylactic antibody

pharmaphorum

The antibody-based drug has been cleared by the European Commission with a broad label, covering both full-term and pre-term babies and those with a range of health conditions that could make the vulnerable to RSV, said the two pharma groups in a statement. It is the first approval for Beyfortus (nirsevimab) by any regulatory authority.

article thumbnail

PharmaShots' Key Highlights of First Quarter 2023

PharmaShots

of the newly combined company The combined companies’ focus is to advance Elicio’s lymph node-targeting amphiphile technology to develop immunotherapies & also focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors is currently being evaluated in the P-I trial (AMPLIFY-201) for PDAC and CRC.

FDA 40